The most notable significant differences (KIT D816Vpos. versus KIT D816H/Ypos. versus KITneg. MCL ± AHN) included age (median 68 versus 55 versus 56 years, p < 0.02), vitamin B12 levels (median 1597 versus 300 versus 3091 μg/L, p < 0.04), HRM (66% versus 33% versus 29%, p = 0.03) and survival (2.6 versus 1.7 versus 0.9 years; p = 0.04). This evidence concerns the gene KIT and mantle cell lymphoma.